Xenon Acquires Next-Generation Epilepsy Drug from 1st Order Pharmaceuticals
Pittsboro, NC – April 26, 2017
1st Order acquired 1OP2198 from an undisclosed third party, and Xenon will have to honor financial responsibilities under that deal. The firm expects to make up-front and milestone payments of $1.1 million in 2017. Moving forward, payments due to 1st Order and the third party could include $1 million in clinical development milestones, up to $13 million in regulatory milestones, and up to about $33.6 million in sales-based and other milestones, plus sales royalties.
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.
Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
